Standard BioTools Inc. Revenues
Standard BioTools Inc. (LAB) reported Revenues of $26.43 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-08.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2018-08-08
- Standard BioTools Inc. revenues for the quarter ending 2018-06-30 was $26.43M, a 10.52% increase year-over-year.
- Standard BioTools Inc. revenues for the quarter ending 2018-03-31 was $25.25M, a 1.12% decline year-over-year.
- Standard BioTools Inc. revenues for the quarter ending 2017-12-31 was $27.75M, a 10.61% increase year-over-year.
- Standard BioTools Inc. revenues for the quarter ending 2017-09-30 was $24.75M, a 11.52% increase year-over-year.
- Standard BioTools Inc. revenues for fiscal 2017 was $101.94M, a 2.40% decline from fiscal 2016.
- Standard BioTools Inc. revenues for fiscal 2016 was $104.45M, a 8.95% decline from fiscal 2015.
- Standard BioTools Inc. revenues for fiscal 2015 was $114.71M, a 1.50% decline from fiscal 2014.
- Standard BioTools Inc. revenues for fiscal 2014 was $116.46M, a 63.60% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2018-06-30 | $26.43M 10-Q · filed 2018-08-08 | $51.68M 10-Q · filed 2018-08-08 | $79.42M derived: sum of 3 quarters · filed 2018-08-08 | $104.17M derived: sum of 4 quarters · filed 2018-08-08 |
| 2018-03-31 | $25.25M 10-Q · filed 2018-05-08 | $52.99M derived: sum of 2 quarters · filed 2018-05-08 | $77.74M derived: sum of 3 quarters · filed 2018-05-08 | $101.65M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-12-31 | $27.75M 10-K · filed 2018-03-08 | $52.49M derived: sum of 2 quarters · filed 2018-03-08 | $76.40M derived: sum of 3 quarters · filed 2018-08-08 | $101.94M 10-K · filed 2018-03-08 |
| 2017-09-30 | $24.75M 10-K · filed 2018-03-08 | $48.66M derived: sum of 2 quarters · filed 2018-08-08 | $74.19M 10-Q · filed 2017-11-07 | $99.28M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-06-30 | $23.91M 10-Q · filed 2018-08-08 | $49.45M 10-Q · filed 2018-08-08 | $74.53M derived: sum of 3 quarters · filed 2018-08-08 | $96.72M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | $25.53M 10-Q · filed 2018-05-08 | $50.62M derived: sum of 2 quarters · filed 2018-05-08 | $72.81M derived: sum of 3 quarters · filed 2018-05-08 | $100.98M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $25.08M 10-K · filed 2018-03-08 | $47.27M derived: sum of 2 quarters · filed 2018-03-08 | $75.44M derived: sum of 3 quarters · filed 2018-03-08 | $104.45M 10-K · filed 2018-03-08 |
| 2016-09-30 | $22.19M 10-K · filed 2018-03-08 | $50.36M derived: sum of 2 quarters · filed 2018-03-08 | $79.36M 10-Q · filed 2017-11-07 | $110.08M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $28.17M 10-K · filed 2018-03-08 | $57.17M 10-Q · filed 2017-08-08 | $87.89M derived: sum of 3 quarters · filed 2018-03-08 | $116.54M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $29.00M 10-K · filed 2018-03-08 | $59.73M derived: sum of 2 quarters · filed 2018-03-08 | $88.37M derived: sum of 3 quarters · filed 2018-03-08 | $116.99M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $30.72M 10-K · filed 2017-03-03 | $59.37M derived: sum of 2 quarters · filed 2017-03-03 | $87.98M derived: sum of 3 quarters · filed 2017-03-03 | $114.71M 10-K · filed 2018-03-08 |
| 2015-09-30 | $28.64M 10-K · filed 2017-03-03 | $57.26M derived: sum of 2 quarters · filed 2017-03-03 | $83.99M 10-Q · filed 2016-11-09 | $117.48M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-06-30 | $28.62M 10-K · filed 2017-03-03 | $55.35M 10-Q · filed 2016-08-09 | $88.84M derived: sum of 3 quarters · filed 2017-03-03 | $118.47M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-03-31 | $26.73M 10-K · filed 2017-03-03 | $60.22M derived: sum of 2 quarters · filed 2017-03-03 | $89.85M derived: sum of 3 quarters · filed 2017-03-03 | $117.46M derived: sum of 4 quarters · filed 2017-03-03 |
| 2014-12-31 | $33.49M 10-K · filed 2016-02-29 | $63.13M derived: sum of 2 quarters · filed 2016-02-29 | $90.73M derived: sum of 3 quarters · filed 2016-02-29 | $116.46M 10-K · filed 2017-03-03 |
| 2014-09-30 | $29.64M 10-K · filed 2016-02-29 | $57.24M derived: sum of 2 quarters · filed 2016-02-29 | $82.97M 10-Q · filed 2015-11-09 | $103.85M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $27.61M 10-K · filed 2016-02-29 | $53.33M 10-Q · filed 2015-08-10 | $74.21M derived: sum of 3 quarters · filed 2016-02-29 | $92.50M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $25.72M 10-K · filed 2016-02-29 | $46.60M derived: sum of 2 quarters · filed 2016-02-29 | $64.89M derived: sum of 3 quarters · filed 2016-02-29 | $82.37M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $20.88M 10-K · filed 2015-02-26 | $39.17M derived: sum of 2 quarters · filed 2015-02-26 | $56.65M derived: sum of 3 quarters · filed 2015-02-26 | $71.18M 10-K · filed 2016-02-29 |
| 2013-09-30 | $18.29M 10-K · filed 2015-02-26 | $35.77M derived: sum of 2 quarters · filed 2015-02-26 | $50.30M 10-Q · filed 2014-11-06 | $65.96M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $17.48M 10-K · filed 2015-02-26 | $32.02M 10-Q · filed 2014-08-04 | $47.67M derived: sum of 3 quarters · filed 2015-02-26 | $60.46M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $14.54M 10-K · filed 2015-02-26 | $30.19M derived: sum of 2 quarters · filed 2015-02-26 | $42.98M derived: sum of 3 quarters · filed 2015-02-26 | $55.92M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $15.66M 10-K · filed 2014-03-12 | $28.44M derived: sum of 2 quarters · filed 2014-03-12 | $41.39M derived: sum of 3 quarters · filed 2014-03-12 | $52.33M 10-K · filed 2015-02-26 |
| 2012-09-30 | $12.78M 10-K · filed 2014-03-12 | $25.73M derived: sum of 2 quarters · filed 2014-03-12 | $36.67M 10-Q · filed 2013-11-07 | $49.67M derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-06-30 | $12.95M 10-K · filed 2014-03-12 | $23.89M 10-Q · filed 2013-08-07 | $36.89M derived: sum of 3 quarters · filed 2014-03-12 | $47.48M derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-03-31 | $10.95M 10-K · filed 2014-03-12 | $23.94M derived: sum of 2 quarters · filed 2014-03-12 | $34.54M derived: sum of 3 quarters · filed 2014-03-12 | $45.11M derived: sum of 4 quarters · filed 2014-03-12 |
| 2011-12-31 | $13.00M 10-K · filed 2013-03-12 | $23.59M derived: sum of 2 quarters · filed 2013-03-12 | $34.17M derived: sum of 3 quarters · filed 2013-03-12 | $42.87M 10-K · filed 2014-03-12 |
| 2011-09-30 | $10.60M 10-K · filed 2013-03-12 | $21.17M derived: sum of 2 quarters · filed 2013-03-12 | $29.87M 10-Q · filed 2012-11-09 | $40.22M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | $10.58M 10-K · filed 2013-03-12 | $19.27M 10-Q · filed 2012-08-14 | $29.63M derived: sum of 3 quarters · filed 2013-03-12 | $38.09M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $8.70M 10-K · filed 2013-03-12 | $19.05M derived: sum of 2 quarters · filed 2013-03-12 | $27.52M derived: sum of 3 quarters · filed 2013-03-12 | $35.54M derived: sum of 4 quarters · filed 2013-03-12 |
| 2010-12-31 | $10.36M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $18.82M derived: sum of 2 quarters · filed 2013-03-12 | $26.84M derived: sum of 3 quarters · filed 2013-03-12 | $33.56M 10-K · filed 2013-03-12 |
| 2010-09-30 | $8.47M 10-Q · filed 2011-11-14 | $16.49M derived: sum of 2 quarters · filed 2011-11-14 | $23.20M 10-Q · filed 2011-11-14 | |
| 2010-06-30 | $8.02M 10-Q · filed 2011-08-09 | $14.74M 10-Q · filed 2011-08-09 | ||
| 2009-12-31 | $25.41M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |